Remove 2017 Remove COVID-19 Remove FDA Remove World Health
article thumbnail

How the Medical Industry Can Help Combat the Current Coronavirus Crisis

Exeed Regulatory Compliance

A novel coronavirus, now called SARS-CoV-19, was first detected in the Hubei province of China in early December 2019. Secretary of the Department of Health and Human Services (HHS) has declared a public health emergency. There is now an FDA policy released on 29 Feb. This will require a large supply.

article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2023 – May And June

SQA

Experience with large-scale events such as Hurricane Maria and the COVID-19 pandemic, and more recent geopolitical events, have cast a wider lens on global supply chain and distribution vulnerabilities. The model provides expanded guidance that reflects new insight and best practices that have emerged in the past several years.

FDA 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2023 – January

SQA

A new template for the Certificate of a Pharmaceutical Product will be put into use in line with China’s pharmaceutical export practices and the latest World Health Organization (WHO) guidelines. The electronic certificate and the paper version are equally authentic.

article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2022 – September/October

SQA

19 Medical Rehabilitation Equipment. The EC presented a first draft for public comment to the revision of Annex 1 in 2017. Medicine shortages and reduced availability of medicine represent an increasing issue across the European Union (EU) and the globe, which has been amplified by the COVID-19 pandemic.

FDA 40